MAGI MAGDI KHALIL MD, PHD
Prescription History 1700948635
Internal Medicine - Medical Oncology in Gloucester, VA


Quality Rating: 94.07 out of 100 score

NPI Status: Active since December 15, 2006

Contact Information

7544 MEDICAL DR
GLOUCESTER, VA
ZIP 23061
Phone: (804) 693-9037
Fax: (804) 693-9486

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MAGI MAGDI KHALIL MD, PHD, an active Medical Oncology specialist practicing in Gloucester, VA. Our medical registry currently tracks 14 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 432 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 174 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
VA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.8
Peer Average Days Supply1,131
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56,023.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,668.60

State Avg Cost Per Claim

$3,036.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 174
30-Day Fills 469.0
Days Supply 14,055
VA State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills148.3
Peer Average Days Supply4,433
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 185.2% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,296.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.93

State Avg Cost Per Claim

$28.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.9
Days Supply 345
VA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply510
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $672.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.05

State Avg Cost Per Claim

$18.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,078
VA State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills118.3
Peer Average Days Supply3,347
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 50.7% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,548.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$570.78

State Avg Cost Per Claim

$843.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Erleada

Generic Formulation: ApalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
VA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.1
Peer Average Days Supply783
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $328,835.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,297.21

State Avg Cost Per Claim

$14,704.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 44.8
Days Supply 1,345
VA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills59.2
Peer Average Days Supply1,751
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $443.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.76

State Avg Cost Per Claim

$38.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
VA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply600
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $193,598.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,133.17

State Avg Cost Per Claim

$15,142.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply599
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,144.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,701.94

State Avg Cost Per Claim

$2,345.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,008
VA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply830
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $561,371.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,593.65

State Avg Cost Per Claim

$14,350.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 49.0
Days Supply 1,470
VA State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills137.4
Peer Average Days Supply4,107
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.0% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $443.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.30

State Avg Cost Per Claim

$37.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 361
VA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills56.5
Peer Average Days Supply1,001
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.3% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $103.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.94

State Avg Cost Per Claim

$6.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Revlimid

Generic Formulation: LenalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
VA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,081
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $301,137.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,821.08

State Avg Cost Per Claim

$18,069.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
VA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.5
Peer Average Days Supply487
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $120,273.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,022.75

State Avg Cost Per Claim

$15,570.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 504
VA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,847
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.3% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,764.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$650.96

State Avg Cost Per Claim

$925.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MAGI MAGDI KHALIL MD, PHD provides transparency into local medical care patterns within Gloucester, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.